Ocugen Inc
Change company Symbol lookup
Select an option...
OCGN Ocugen Inc
NEGG Newegg Commerce Inc
PHX PHX Minerals Inc
IRT Independence Realty Trust Inc
RLAY Relay Therapeutics Inc
CVU CPI Aerostructures Inc
MA Mastercard Inc
WDBG Neuro-Hitech Inc
GLRY Inspire Faithward Mid Cap Momentum ETF
WCC Wesco International Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccine for COVID-19. The Company's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine candidate is focused on developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). It is developing OCU200, a biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.

Closing Price
$0.83
Day's Change
-0.0566 (-6.38%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.907
Day's Low
0.83
Volume
(Light)
Volume:
4,584,488

10-day average volume:
9,975,315
4,584,488

DEADLINE ALERT for BRDS, OLPX, CURV, GNRC: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

11:00 am ET January 17, 2023 (Globe Newswire) Print
DEADLINE ALERT for BRDS, OLPX, CURV, GNRC: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of ShareholdersGlobeNewswireJanuary 17, 2023

BENSALEM, Pa., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

Bird Global, Inc. f/k/a Switchback II Corporation (NYSE: BRDS)

Class Period: May 14, 2021 - November 14, 2022

Lead Plaintiff Deadline: January 17, 2023

The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose that: (1) Bird was improperly recording Sharing Revenue for certain trips by its customers where collection was not probable; (2) as such, Bird overstated its Sharing Revenue for the relevant quarters and fiscal year during the Class Period; (3) Bird failed to disclose that its internal controls were not effective as they relate to calculating Sharing Revenue recognition; (4) as a result, Bird would need to restate its previously disclosed Sharing Revenue; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Olaplex Holdings, Inc. (NASDAQ: OLPX

Class Period: September 2021 IPO

Lead Plaintiff Deadline: January 17, 2023

The complaint alleges that the defendants made false and/or misleading statements and/or failed to disclose that: (1) macroeconomic pressures and competition in the haircare market were more robust than the Company had represented to investors; (2) accordingly, the Company was unlikely to maintain its sales and revenue momentum; and (3) as a result, it was unlikely that the Company would be able to achieve the financial and operational growth projected in the Offering Documents; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Torrid Holdings Inc. (NYSE: CURV)

Class Period: July 2021 IPO

Lead Plaintiff Deadline: January 17, 2023

The complaint alleges that the defendants made false and/or misleading statements and/or failed to disclose: (1) that in the first half of 2021 Torrid had experienced a temporary surge in demand as a result of changed consumer behaviors in response to the COVID-19 pandemic and government stimulus and that such ephemeral demand trends had dissipated and were not internally projected to continue following the IPO; (2) that Torrid was suffering from severe supply chain disruptions caused by the emergence of the Delta variant of COVID-19, which had first emerged in May 2021; (3) that Torrid was running materially below historical inventory levels as a result of supply chain disruptions; (4) that, as a result of the foregoing, Torrid did not have sufficient inventory to meet expected consumer demand for its fiscal third quarter of 2021; (5) that, as a result of the foregoing, late inventory arrival had materially impaired the Company from effectively matching consumer buying trends, creating an undisclosed risk of increased markdowns and promotional activities necessary to sell undesirable inventory; (6) that Torrid's CFO planned to retire shortly after the IPO; and (7) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Generac Holdings Inc. (NYSE: GNRC)

Class Period: April 29, 2021 - November 1, 2022

Lead Plaintiff Deadline: January 30, 2023

Shareholders with $150,000 losses or more are encouraged to contact the firm.

The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose: (1) the full scope of the economic harm flowing from the defective SnapRS units; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith

Howard G. Smith, Esquire

215-638-4847

888-638-4847

howardsmith@howardsmithlaw.com

www.howardsmithlaw.com



comtex tracking

COMTEX_422823450/2010/2023-01-17T11:00:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.